The multiple myeloma market size is expected to grow from USD 24.12 billion in 2025 to USD 25.88 billion in 2026 and is forecast to reach USD 38.09 billion by 2031 at 8.03% CAGR over 2026-2031. This report is Segmented by Drug Class (Proteasome Inhibitors, Immunomodulators, Anti-CD38 MAbs, and More), Therapy Type (Monotherapy, Combination Therapy), Route of Administration (Oral, Intravenous, Subcutaneous), Distribution Channel (Hospital, Retail, Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, MEA, South America). Market Forecasts are Provided in Value (USD).
Other drivers and restraints analyzed in the detailed report include:
Manufacturing ceilings constrain supply, but investment momentum is strong. Legend Biotech’s upcoming plant should lower per-dose costs by 35%, while FDA draft rules on closed-system bioreactors may let community hospitals capture production economics locally. Should point-of-care models prevail, the multiple myeloma market could double cellular-therapy penetration by the end of the forecast horizon, diverting revenue from oral immunomodulators that today dominate maintenance settings.
Combination protocols accounted for 61.27% of 2025 prescriptions and will grow at a 9.63% CAGR, driven by quadruplets pairing anti-CD38 monoclonals with lenalidomide-bortezomib backbones. The MAIA trial reported a 44% reduction in progression risk, prompting NCCN to elevate the triplet to preferred frontline care. Monotherapy remains material in maintenance, where single-agent lenalidomide offers convenience for transplant recipients achieving MRD negativity. The multiple myeloma market share for quadruplets is poised to climb once bispecific antibodies are integrated into second-line cocktail studies, with results expected in 2027.
Maintenance monotherapy enjoys an identical 9.63% CAGR to combination therapy because ongoing MRD-guided de-escalation allows oncologists to extend treatment to capture survival gains. Ixazomib’s 26-month median progression-free survival in maintenance secured FDA approval in 2024, and real-world European data show 70% two-year progression-free survival with single-agent subcutaneous daratumumab. Sequencing strategy, more than regimen intensity, is now the key determinant of long-term outcomes.
Asia-Pacific will post the fastest regional growth rate at 12.27% CAGR. China approved Carvykti at CNY 1.2 million, immediately adding it to the national reimbursement list with 70% coverage, thereby making cellular therapy accessible to 15,000 patients per year. Japan reimbursed teclistamab at JPY 25 million per patient, aligning with cost-effectiveness thresholds, while Australia reduced patient co-pays for isatuximab to AUD 42 per fill. India slashed lenalidomide caps, yet rural penetration remains low, underscoring the urban-rural care divide in the multiple myeloma industry.
Germany and the UK granted positive health-technology assessments for teclistamab and Carvykti, embedding managed-access agreements that tie payments to five-year overall survival targets. France’s early-access route shortened time-to-reimbursement by nine months, while Italy’s essential-medicines list now includes subcutaneous daratumumab. Sub-Saharan Africa and most of the Middle East lag due to funding deficits, save for the UAE, which approved government reimbursement for daratumumab in 2025, signaling incremental progress in access equity.
Global Multiple Myeloma Market Trends and Insights
Rising Prevalence of Multiple Myeloma
Incident cases continue to climb as diagnostic sensitivity improves and populations age. The International Agency for Research on Cancer estimated 176,000 new diagnoses worldwide in 2024 and projects 210,000 annually by 2030. A median diagnosis age near 69 ensures that the post-war baby-boom cohort sustains patient inflows, while enhanced imaging tools detect smoldering disease earlier, extending treatment sequences across more therapy lines. Ethnic disparities also shape demand, with individuals of African descent experiencing double the incidence of their European-descent counterparts, prompting targeted U.S. screening initiatives. As median survival now exceeds 8 years, each additional patient contributes durable revenue streams despite per-patient costs plateauing.Launch Pace of Next-Gen Immunotherapies
Between January 2024 and December 2025, regulators cleared three bispecific T-cell engagers and two CAR-T constructs, compressing clinic-to-market timelines to under 9 months. Off-the-shelf agents such as teclistamab generated USD 890 million in 2025 sales as community oncologists administered subcutaneous injections without leukapheresis infrastructure. Supplemental filings to move these drugs into second-line use could divert USD 2 billion annually from triplet regimens if ongoing trials confirm non-inferiority. Competitive differentiation is shifting toward safety metrics, such as cytokine release syndrome incidence, as efficacy rates converge.High Price of Novel Therapies
CAR-T infusions cost USD 475,000 in the United States, and bispecific antibodies cost USD 23,000 per month, placing curative-intent care beyond reach for 60% of the world, lacking catastrophic coverage. India’s median household income of USD 2,400 renders an annual isatuximab course of USD 280,000 unaffordable without subsidy, while China negotiated a 70% discount on domestic CAR-T products to bring costs below USD 150,000. Outcomes-based deals, such as Novartis refunding 50% of the price of tisagenlecleucel for non-responders, are emerging but require sophisticated data infrastructure.Other drivers and restraints analyzed in the detailed report include:
- Rapid Aging of High-Income Populations
- Favorable Reimbursement in United States and Europe
- Drug-Resistance & Severe Adverse Events
Segment Analysis
Immunomodulators accounted for 34.82% of 2025 revenue, yet CAR-T and cell-based products are forecast to grow at a 10.06% CAGR, underscoring the pivot toward durable remissions in earlier lines. Anti-BCMA constructs are replacing proteasome inhibitors in third-line care, as belantamab mafodotin’s revised dosing halves the incidence of corneal toxicity. The multiple myeloma market size for CAR-T is presently limited by the apheresis bottleneck, yet planned capacity additions could unlock new demand curves beyond 2027. Allogeneic off-the-shelf candidates like UCART19 achieved 45% complete remission rates in Phase I, hinting at future disruption once durability concerns are resolved.Manufacturing ceilings constrain supply, but investment momentum is strong. Legend Biotech’s upcoming plant should lower per-dose costs by 35%, while FDA draft rules on closed-system bioreactors may let community hospitals capture production economics locally. Should point-of-care models prevail, the multiple myeloma market could double cellular-therapy penetration by the end of the forecast horizon, diverting revenue from oral immunomodulators that today dominate maintenance settings.
Combination protocols accounted for 61.27% of 2025 prescriptions and will grow at a 9.63% CAGR, driven by quadruplets pairing anti-CD38 monoclonals with lenalidomide-bortezomib backbones. The MAIA trial reported a 44% reduction in progression risk, prompting NCCN to elevate the triplet to preferred frontline care. Monotherapy remains material in maintenance, where single-agent lenalidomide offers convenience for transplant recipients achieving MRD negativity. The multiple myeloma market share for quadruplets is poised to climb once bispecific antibodies are integrated into second-line cocktail studies, with results expected in 2027.
Maintenance monotherapy enjoys an identical 9.63% CAGR to combination therapy because ongoing MRD-guided de-escalation allows oncologists to extend treatment to capture survival gains. Ixazomib’s 26-month median progression-free survival in maintenance secured FDA approval in 2024, and real-world European data show 70% two-year progression-free survival with single-agent subcutaneous daratumumab. Sequencing strategy, more than regimen intensity, is now the key determinant of long-term outcomes.
Complete Report Scope:
- By Drug Class
- Proteasome Inhibitors
- Immunomodulators (IMiDs)
- Anti-CD38 mAbs
- Anti-BCMA Therapies (mAbs, ADCs)
- CAR-T & Cell-based Therapies
- Others (HDACi, Alkylating Agents)
- By Therapy Type
- Monotherapy
- Combination Therapy
- By Route of Administration
- Oral
- Intravenous
- Sub-cutaneous
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
North America generated 44.08% of global revenue in 2025, buoyed by Medicare coverage expansions and a network of 280 certified CAR-T centers. Four novel therapies cleared FDA review in 2025, cutting launch lag to nine months, while Canada’s 45% price cut for Carvykti and Mexico’s inclusion of subcutaneous daratumumab in public formularies broadened regional access.Asia-Pacific will post the fastest regional growth rate at 12.27% CAGR. China approved Carvykti at CNY 1.2 million, immediately adding it to the national reimbursement list with 70% coverage, thereby making cellular therapy accessible to 15,000 patients per year. Japan reimbursed teclistamab at JPY 25 million per patient, aligning with cost-effectiveness thresholds, while Australia reduced patient co-pays for isatuximab to AUD 42 per fill. India slashed lenalidomide caps, yet rural penetration remains low, underscoring the urban-rural care divide in the multiple myeloma industry.
Germany and the UK granted positive health-technology assessments for teclistamab and Carvykti, embedding managed-access agreements that tie payments to five-year overall survival targets. France’s early-access route shortened time-to-reimbursement by nine months, while Italy’s essential-medicines list now includes subcutaneous daratumumab. Sub-Saharan Africa and most of the Middle East lag due to funding deficits, save for the UAE, which approved government reimbursement for daratumumab in 2025, signaling incremental progress in access equity.
List of Companies Covered in this Report:
- Abbvie
- Adaptive Biotechnologies
- Amgen
- Beigene
- Bluebird bio
- Bristol-Myers Squibb
- CEL-Sci
- Cellectis
- Gilead Sciences
- GlaxoSmithKline
- Johnson & Johnson (Janssen Biotech)
- Karyopharm Therapeutics
- Legend Biotech
- MorphoSys
- Novartis
- Oncopeptides AB
- Pfizer
- Regeneron Pharmaceuticals
- Sanofi
- Takeda Pharmaceuticals
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size & Growth Forecasts
6 Competitive Landscape
7 Market Opportunities & Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie
- Adaptive Biotechnologies
- Amgen Inc.
- Beigene
- Bluebird bio
- Bristol-Myers Squibb Company
- CEL-Sci
- Cellectis
- Gilead Sciences
- GlaxoSmithKline
- Johnson & Johnson (Janssen Biotech)
- Karyopharm Therapeutics Inc.
- Legend Biotech
- MorphoSys
- Novartis
- Oncopeptides AB
- Pfizer
- Regeneron Pharmaceuticals
- Sanofi S.A.
- Takeda Pharmaceutical Company Limited
